{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Response that was confirmed on 2 consecutive evaluations during treatment\n\n* CR: Complete disappearance of M-protein from serum \\& urine on immunofixation, \\<5% plasma cells in bone marrow (BM)\n* sCR: CR plus normal FLC ratio \\& absence of clonal cells in BM\n* VGPR: \\>=90% reduction in serum M-component; Urine M-Component \\<100 mg per 24 hours; \\<=5% plasma cells in BM\n* PR: \\>= 50% reduction in serum M-Component and/or Urine M-Component \\>= 90% reduction or \\<200 mg per 24 hours; or \\>= 50% decrease in difference between involved and uninvolved FLC levels","groups":[{"id":"OG000","title":"Sorafenib + Lenalidomide + Dexamethasone"}],"populationDescription":"No participants proceeded to Phase II for evaluation.","reportingStatus":"POSTED","timeFrame":"Duration on Treatment (up to 3 years)","title":"Number of Participants Who Achieve a Confirmed Response (Partial Response [PR], Very Good PR [VGPR], Complete Response [CR], or Stringent CR [sCR]) (Phase II)","type":"PRIMARY"}